MARKETS / NASDAQ / GEHC

NASDAQ · X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS · LARGE CAP

GE HealthCare Technologies Inc. GEHC

5 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$20.6B

▲ 4.8% YoY

Net income

$2.1B

▲ 4.6% YoY

Free cash flow

$1.5B

▼ 3.2% YoY

In brief

What this company does

GE HealthCare Technologies Inc. generates revenue from the sale of medical devices, consumable products, service capabilities, and AI-enabled cloud and software solutions. It has approximately 54,000 employees. It serves customers in over 160 countries with a global team of approximately 9,700 sales professionals and 8,900 field service engineers. Its business is organized into four segments aligned with the industries it serves: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment includes five product lines and associated service capabilities: Molecular Imaging (MI), Computed Tomography (CT), Magnetic Resonance (MR), Women's Health, and X-ray. GE HealthCare Technologies Inc. is a Delaware corporation headquartered in Chicago, Illinois, and it was spun off from the General Electric Company, which now operates as GE Aerospace, on January 3, 2023.

Written from the business description in GE HEALTHCARE TECHNOLOGIES INC.'s annual report to the U.S. Securities and Exchange Commission, filed 4 February 2026. Every sentence was checked against that document before publication.

Growth

USD 20.6B

Revenue, FY2025 · full 5-year series below

Revenue $B Net income $B

FY2025 · Revenue 20.6 · Net income 2.1

Compound annual growth

Revenue

+4.0%

Net income

+2.8%

EPS, diluted

+2.5%

3 yrs

5 yrs

10 yrs

15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

10 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 13.4% · Net 10.4%

ROE

FY2025 · ROE 22.1%

Gross margin40.0%

Operating margin13.4%

Net margin10.4%

Return on assets6.2%

EBITDAUSD 3.0B

Each USD of equity produced 22 cents of profit this year.

Cash & shareholders

USD 227.0M

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 1.5

Net buybacks $M Dividends $M

FY2025 · Dividends 64.0 · Net buybacks 163.0

Dividends paidUSD 64.0M

Net buybacksUSD 163.0M

Share of profit10.9%

Consecutive raises2 years

USD 64.0M in dividends and USD 163.0M in buybacks — 11% of the year's profit went back to shareholders.

Total assetsUSD 36.9B

EquityUSD 10.4B

CashUSD 4.5B

Gross debtUSD 10.0B

Net debtUSD 5.5B

Current ratio1.37×

Net debt stands at 53% of equity.

The 5-year record

5 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021
Revenue $B	20.6	19.7	19.6	18.3	17.6
Operating income $B	2.8	2.6	2.4	2.5	2.8
EBITDA $B	3.0	2.9	2.7	2.8	3.0
Income tax $B	0.6	0.5	0.7	0.6	0.6
Net income $B	2.1	2.0	1.6	1.9	2.2
Free cash flow $B	1.5	1.6	1.7	1.8	1.4
EPS, diluted $	4.55	4.34	3.03	4.22	4.95
Dividend / sh $	0.14	0.12	0.12	·	·
Payout %	3	3	3	0	0
ROE %	22.1	25.6	19.0	20.5	·
Shares out B	·	·	0.46	0.45	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 18 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 58 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityX-Ray Apparatus & Tubes & Related Irradiation Apparatus

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2021